• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Diabetes: Europe, the U.S. and the medtech pendulum’s swing

Diabetes: Europe, the U.S. and the medtech pendulum’s swing

October 17, 2012 By Arezu Sarvestani

GlySure CEO Christopher Jones

GlySure CEO Christopher Jones has a career spanning more than 2 decades and 2 continents, during which he’s seen the medtech regulatory pendulum swing from the Europe to the U.S. and back. 

In an exclusive interview with MassDevice.com, Jones told us about being an American executive in the U.K., changing regulatory timelines and challenges to look for with a Europe-1st strategy.

MassDevice: You have a career that has spanned work with regulators in the U.S. and abroad.  Tell us about your background. 

Christopher Jones:  I’ve got 20-plus years in medical devices and diagnostics, starting in the U.S.

The biggest part of my career was at Nellcor, which eventually, through acquisition, became part of Tyco Healthcare, which is Covidien (NYSE:COV) today. I left a bit before they turned into Covidien.

There we had products – critical care, pulse accelerators, tube tracts – that we were selling globally and that we were putting through for approval in the U.S., Europe and in Japan.

From there I went onto Tensys Medical which was a continuous non-invasive blood pressure company. There we were really focused on the U.S. market and had U.S. approvals.

Now I have come over to the U.K., where I’m running GlySure. GlySure is developing a continuous glucose monitor for use in the hospital. The reason I ended up here is because the U.S. is the biggest market for this product and when they got to the point of reaching proof of concept, they really wanted to have a U.S. focus to the company.

Which is why they first brought Bill Moffitt, who is our chairman and who is based in Chicago, who was CEO of i-STAT and CEO of Nanosphere. And then they recruited me.

We’ve firmly got our eye on the U.S., but at the moment we are absolutely driving forward with a Europe-1st strategy, because the regulatory path for CE Mark is a bit clearer right now. In fact we’ve seen several of our competitors coming over to Europe looking at the same approach.

MassDevice: The Europe-1st strategy is a popular one these days.  How long has it been that way?

CJ: What I find interesting is throughout my career I’ve seen the regulatory timelines and the differences in timing between U.S. and Europe change and go back and forth.

"The value of the CE Mark lies in what you do with it next in being able to build a network of key opinion leaders and build a credible sales platform."
– GlySure CEO Christopher Jones

There was a time back in the early ’90s where you could get to Europe faster. We were launching 1st in Europe with devices and systems at Nellcor.

Then all of a sudden things came around and the FDA got faster and we realized all of a sudden that there wasn’t any delay anymore. We were basically doing everything in parallel back then and able to get through FDA approvals on pretty competitive timelines with Europe.

What’s become really obvious over the last 4-5 years is that those timelines between U.S. regulatory and European regulatory have diverged once again. You’re seeing more and more companies go to market 1st in Europe, because they can get the CE Mark faster, then go to the U.S. when they are able to get the data to satisfy the U.S. requirements.

To be fair, there are different focuses. The European system is much more focused on just demonstrating the basic baseline safety of the device, as opposed to performance. They are much more focused on ensuring the device is safe and they put it out in the hands of the doctors to figure out how to use it.

The FDA has a challenge in that they’re responsible for both device regulation and also for overall patient safety and health. They’ve got a role that the European regulators don’t have. That causes them to take a different approach sometimes.

MassDevice: In dealing in both arenas, are there certain experiences that you had with either body that were particularly telling?

CJ: That is a challenging question to answer. I think if you look right now at the market that I’m in, continuous glucose monitoring for the hospital, there have already been 2 companies that have gotten CE Marks for early prototype systems in Europe.

One was Edwards Lifesciences (NYSE:EW) and the other OptiScan (ASX:OIL).  In fact Edwards submitted to the FDA for approval and wasn’t able to get it and eventually backed off.

I won’t get into the details because it’s another company, but if you look at their quarterly earnings you can see the CEO make comments about the challenges they ran into and what the FDA was asking for. In my understanding from looking from his comments, the FDA was looking at usability and asking for usability trials. They made the decision to go on to a 2nd-generation device.

The FDA in June just held a public comment in which they pulled in feedback from the clinical community to get advice on what the performance metrics should be, what testing should be done in order to clear a continuous glucose monitor for use in the U.S.

We think it was a really important step because it provided the FDA with a lot of good feedback. Hopefully they can take that and incorporate that into their thinking, be able to share that with the industry to provide everybody with some direction on approvals. But that’s definitely a different approach than what we’ve seen in Europe.

MassDevice: With that meeting, do you feel that the FDA has been taking steps to fix the diverging timelines?

"While you can get [CE Mark] approval quicker, it doesn’t necessarily mean that you then have all of the clinical proof that clinicians are going to want in order to get widespread adoption."
– GlySure CEO Christopher Jones

CJ: I do. I think it was a very important step to go get feedback from clinicians in the clinical community to guide their decision making. To me that was a very positive step in the right direction. I am eager to get back and talk with them some more about our proposed trials and the feedback they got from the clinicians.

MassDevice: In the medtech community, there’s sometimes a tendency to romanticize the European regulatory environment. Are there obstacles there that device makers sometimes underestimate?

CJ: I think that’s a challenge that we are clearly aware of. While you can get the approval quicker it doesn’t necessarily mean that you then have all of the clinical proof that clinicians are going to want in order to get widespread adoption. But what you do is go out to the early adopters and start to work them to then build that further clinical evidence to create support for the device.

MassDevice: On the other side of the pond, are there benefits to the FDA pathways that device makers sometimes take for granted?

CJ: I think the answer to that is absolutely yes. When you talk to VCs that are looking at funding companies and if you look at exiting companies, they have a huge premium that they put on FDA above CE Mark.

The CE Mark on its own without data, without usage, confers a small amount of benefit to a startup company. It really is when that CE Mark is backed up by clinical usage and data and opinion leaders that can talk about product performance that it becomes valuable.

Whereas the FDA approval is more rigorous, that on its own, in talking to people, is recognized as such tends to confer for the bigger bump in evaluation to the company.

MassDevice: What do you think are some of the most important cultural differences you’ve see in dealing with the FDA versus dealing with European regulators?

CJ: I’ll talk about the one that fascinates me the most, because it’s 1 of those that I view as just a difference. Not necessarily 1 being better or worse than the other.

“The CE Mark on its own without data, without usage, confers a small amount of benefit to a startup company.”
– GlySure CEO Christopher Jones

When you go and talk with the FDA about studies and patient numbers, many times the FDA is looking to make sure you’ve got enough patients in your study to get a very representative sample, to ensure that there aren’t outliers out there that you’ve missed that could be safety risks. While you probably can never touch enough patients to eliminate any risk, there is certainly a value in pushing for more patents to minimize the risk.

The European regulators almost take the opposite approach. When they are looking at study design, they are pushing it down to get the smallest number of human subjects possible, because there are ethical concerns in Europe about doing studies on critically ill patients in hospitals. There are 2 very valid opinions.

One approach, which is, "What testing is possible to minimize risk once the product is a launched?" And the other one which says, "Let’s minimize the human testing in order to reduce the risk to the subjects of the test."

Both take the regulators in very different direction in terms of number of patents required for approval.

MassDevice: A lot of companies are looking to the European market as a launching point. Do you have any tips or warnings for them when they are coming to Europe?

CJ: I think it’s really obvious, but Europe is a very large place and very diverse – much more diverse than the U.S. It’s really important to take a country-by-country approach because there are stark differences between Northern and Southern Europe and Eastern and Western Europe. You need to get some local experts to help you figure out which markets you want to tackle first, which country is best served by direct sales, which country can be best served by distribution.

There are a lot of differences in the healthcare system from country to country. It takes some time, some planning and a whole lot of local knowledge before you want to jump in. As a small company I think it’s probably wise to pick a few markets and start an approach without trying to go too broad too quickly.

MassDevice: In terms of the CE Mark not conferring an immediate bump in sales, any words of warning or temperance for startups coming that way?

CJ: That’s an interesting question. I think my personal belief is that the value of the CE Mark lies in what you do with it next in being able to build a network of key opinion leaders and build a credible sales platform.

A lot of companies are coming over to get experience in the market, and it’s important to have local experts on the ground in the countries where you want to go to market. That way you can get the result, the customer updates, the feedback that you’re looking for.

MassDevice: Last but not least, lets switch topics just a little bit. I know GlySure doesn’t yet have any products for sale in the U.S. Is the medical device tax on your radar?

CJ: I think the short answer is not yet, because we are not on the market yet. In many ways I think it’s probably more of an issue for existing companies because their pricing is already set in the market. A company launching a brand new product is just going to look at that device tax and take it into account when they figure out what their plans are for marketing the product in the U.S.

Filed Under: News Well Tagged With: GlySure, MassDevice Q&A

In case you missed it

  • Entegris opens Life Sciences Technology Center in Massachusetts
  • Glucose monitor maker Know Labs expands leadership team
  • inHeart wins FDA clearance for 3D cardiac modeling software
  • How Glytec is advancing insulin management in the hospital
  • Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
  • FDA clears RapidAI’s pulmonary embolism triage platform
  • Report: Dexcom in talks to acquire Insulet
  • Henry Schein investors push back on executive pay
  • Alcon to pay $60M to acquire Kala Pharmaceuticals’ dry eye treatment
  • Creo Medical inks collaboration agreement with Intuitive
  • MedTrace Pharma moves forward on 15 O-water imaging tech
  • HistoSonics, GE Healthcare agree to integrate ultrasound into sonic beam liver therapy
  • Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
  • FDA says Philips ventilator recall produced over 21,000 device reports, 124 deaths
  • Boston Scientific’s Acurate Neo2 valve performs well in studies
  • MicroTransponder reports first commercial implantation of its stroke rehab neurostim system

RSS From Medical Design & Outsourcing

  • Varta presents microbattery product portfolio at Computex 2022
    Varta will present its broad product portfolio of microbatteries, which make a wide range of future-proof applications possible, at Computex in Taipei starting today. Varta’s microbattery product portfolio ranges from rechargeable lithium-ion button cells to nickel metal hydride button cells, primary silver oxide cells, primary lithium button cells and cylindrical lithium batteries to hydrogen gas… […]
  • Entegris opens Life Sciences Technology Center in Massachusetts
    Entegris (Nasdaq:ENTG) announced today that it opened a new Life Sciences Technology Center in Billerica, Massachusetts. The new Life Sciences Technology Center was built to offer life sciences customers the opportunity to leverage Entegris’ cold-chain supply expertise to optimize processes, reduce costs and increase speed to market. Get the full story at our sister site,… […]
  • MedAcuity hires SVP of business development
    Medtech software development firm MedAcuity today said it has hired Simon Johnson as SVP of business development. Westford, Massachusetts-based MedAcuity said Johnson previously built the client partner team and managed strategic clients at digital consultancy Mobiquity. He also served as SVP of client services at GreenPages Technologies, responsible for driving services revenue growth leading to… […]
  • Henry Schein investors push back on executive pay
    Nearly half of Henry Schein (Nasdaq:HSIC) shareholders who voted at this month’s annual meeting voted against the company’s pay packages for top executives, according to a new SEC filing. About 48.5% of voting shareholders voted against the company’s executive pay plan in what’s known as the Say-on-Pay vote, according to vote results of the May… […]
  • Creo Medical inks collaboration agreement with Intuitive
    Creo Medical Group (LON: CREO) announced today that it has signed a multi-year collaboration agreement with Intuitive to make certain Creo surgical technologies compatible with the surgical robotic giant’s systems. The London exchange reacted by sending CREO shares up more than 4% to 100 pence apiece by the close of trading today. As of midday… […]
  • MedTrace Pharma moves forward on 15 O-water imaging tech
    MedTrace Pharma announced the first person scanned in its Rapid-Water-Flow Phase 3 clinical trial, further testing its tech to bring 15 O-water to imaging. The first subject scan took place at Aarhus University Hospital in Denmark, using 15 O-water produced, dosed and injected through MedTrace’s P3 automated delivery system. The clinical trial aims to evaluate… […]
  • Zimmer Biomet narrowly avoids shareholder rebuke on executive pay
    An unusually large share of Zimmer Biomet (NYSE:ZBH) investors voted against the orthopedics company’s pay packages for top executives at the annual shareholder meeting. About 54% of voting shareholders supported the pay packages of the company’s five top-paid executives at the May 13 meeting, according to results filed with the SEC yesterday. In 2021, nearly 93%… […]
  • BD, Mitsubishi Gas Chemical partner on better materials for plastic syringes
    BD (NYSE:BDX) announced that it partnered with Mitsubishi Gas Chemical Company on applying new technology to pre-fillable syringes. MGC develops the Oxycapt technology designed to integrate the best of plastic and glass for plastic syringes. BD and Tokyo-based MGC will work together to apply Oxycapt technology to the next generation of pre-fillable syringes (PFS) for advanced… […]
  • Ambu replaces CEO with new leadership
    Ambu today said it has hired board member Britt Meelby Jensen to replace CEO Juan Jose Gonzalez, effective tomorrow. “Since Juan Jose Gonzalez joined as CEO in 2019, Ambu has made good progress and achieved important milestones on the strategic transformation into the world’s largest single-use endoscopy company,” Ambu Chair Jørgen Jensen said in a… […]
  • AdvaMed joins Biden’s Joint Supply Chain Resilience Working Group
    AdvaMed executive Abby Pratt has joined the executive committee for the Biden administration’s Joint Supply Chain Resilience Working Group, the medtech industry association said today. The working group’s members from government and industry will assist with implementation of the National Strategy for a Resilient Public Health Supply Chain. Pratt oversees supply chain issues as SVP… […]
  • Toray develops new stretchable film for medical devices
    Toray Industries has a new stretchable film based on its proprietary polymer Reactis technology, with potential applications that include robotics and biological and industrial sensors. Tokyo-based Toray said it shipped samples to customers and plans research and development efforts to commercialize the new grade of film. “Recent years have increased the potential for developing stretchable… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS